Purchase

Recombinant Mouse gp130/IL6ST protein (rFc Tag)(HPLC verified)

Species

Mouse

Purity

>90 %, SDS-PAGE
>90 %, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg1631


Product Information

Purity >90 %, SDS-PAGE
>90 %, SEC-HPLC
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Mouse gp130 protein Gln23-Glu617 (Accession# Q00560) with a rabbit IgG Fc tag at the C-terminus.
GeneID 16195
Accession Q00560
PredictedSize 92.9 kDa
SDS-PAGE 90-125 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Glycoprotein 130 (gp130, also known as IL6ST, CD130 or IL6-beta) is a ubiquitously expressed, signal-transducing receptor that serves as the signal transduction unit for IL-6 family of cytokines, including IL-6, IL-11, IL-27, leukemia inhibitory factor (LIF), OSM, ciliary neurotrophic factor (CNTF), cardiotrophin 1 (CT-1), and cardiotrophin-like cytokine (CLC). These cytokines signal through the gp130/Jak/STAT pathway. Binding of IL-6 to IL-6R induces gp130 homodimerization and formation of a high-affinity receptor complex, which activates Jaks. That causes phosphorylation of gp130 tyrosine residues which in turn activates STAT3. gp130 is a type I transmembrane protein, and can also exist as a soluble form (sgp130). sgp130 binds to sIL-6R/IL-6 complexes and prevents their interactions with membrane-anchored gp130 on target cells.

References:

1. T Taga, et al. (1997) Annu Rev Immunol. 15:797-819. 2. J S Silver, et al. (2010) J Leukoc Biol. 88(6):1145-56. 3. P C Heinrich, et al. (1998) Biochem J. 334 ( Pt 2):297-314. 4. F A Montero-Julian, et al. (1997) Clin Cancer Res. 3(8):1443-51.